PEPared Study

Rates of bacterial sexually transmitted infections (STIs), such as syphilis, gonorrhea, and chlamydia have increased greatly in the past year, with notable disparities among sexual minority men (SMM). Recently, the Centers for Disease Control and Prevention (CDC) has developed guidelines for the use of doxycycline post-exposure prophylaxis (Doxy PEP) as a biomedical prevention strategy for bacterial STIs. The development of federal guidelines signifies a distinct shift in STI prevention; yet there is sparse data on the acceptability and usability of doxycycline as a STI prevention tool, particularly among SMM.

From June 2024 through September 2024, 58 participants enrolled in the American Transformative HIV Study (AMETHST) completed a one-on-one, semi-structured in-depth interview and a cross-sectional, quantitative survey to understand their knowledge, acceptability, and attitudes towards Doxy PEP. Data analysis is currently underway. Study findings have the potential to inform future studies and interventions that seek to increase acceptability and use of Doxy-PEP as a biomedical STI prevention tool.